Although genome-wide association studies identified IRAK1 polymorphisms as a risk factor for SLE (48–50), to our knowledge the current study is the first to provide evidence that specific inhibition of IRAK1 kinase may have therapeutic potential for the prevention of SLE. Here, IRAK1 is linked to systemic lupus erythematosus.